Just attended the presentation. Impressive technology.
key benefits
1: Impressive In Vivo results in mice
2: good survival rates over 90 days
3: the protection from reoccurrence without additional dosage 4: the off shelf treatment from healthy donors ( big advantage compared to using the cells taken from the patients which is faster, cheaper and potential of healthier cells being used instead of compromised cells from the affected patients).
5: patents to 2038
6: develop additional products using other CAR cells.
Ann: SUDA Licenses a Novel iNKT Cell Therapy Platform, page-36
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $147.2M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.3¢ | 14.0¢ | $31.21K | 222.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 632125 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 158860 | 8 |
View Market Depth
| Last trade - 12.12pm 04/09/2024 (20 minute delay) ? |
| ALA (ASX) Chart |